All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
LU 103793
Known as:
LU-103793
, LU103793
Â
Â
National Institutes of Health
Topic mentions per year
Topic mentions per year
1995-2007
0
1
2
3
1995
2007
Related topics
Related topics
1 relation
Broader (1)
cemadotin
Related mentions per year
Related mentions per year
1995-2014
1990
2000
2010
2020
LU 103793
cemadotin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison.
CDR Matt Le Tourneau
,
Ernest Raymond
,
Sandrine J. Faivre
Current pharmaceutical design
2007
The marine ecosystem that has contributed to the discovery of cytarabine and its fluorinated derivative gemcitabine is now…Â
(More)
Is this relevant?
2003
2003
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.
Pierre Kerbrat
,
Véronique Diéras
,
Nikolas Pavlidis
,
Alain Mure Ravaud
,
Jennifer Wanders
,
Pierre Fumoleau
European journal of cancer
2003
LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate…Â
(More)
Is this relevant?
2003
2003
A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
Randolph S. Marks
,
David J L Graham
,
+7 authors
Ferdinand K Addo
American journal of clinical oncology
2003
A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with…Â
(More)
Is this relevant?
2001
2001
Activity of the dolastatin analogue, LU103793, in malignant melanoma.
John B. Smyth
,
M E Boneterre
,
+4 authors
A. Hanauske
Annals of oncology : official journal of the…
2001
LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase…Â
(More)
Is this relevant?
1999
1999
Synthesis and cytostatic properties of structure-simplified analogs of dolastatin 15.
Min-lun Hu
,
Weidong Huang
The journal of peptide research : official…
1999
The linear peptide dolastatin 15 (1), a potent antineoplastic constituent from the shell-less mollusk Dolabella auricularia, has…Â
(More)
Is this relevant?
1998
1998
Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action.
M. Jordan
,
D. Walker
,
Monika de Arruda
,
Teresa Barlozzari
,
Dhabaleswar K. Panda
Biochemistry
1998
Cemadotin (LU103793) (NSC D-669356) is a water-soluble synthetic analogue of dolastatin 15 that inhibits cell proliferation in…Â
(More)
Is this relevant?
1998
1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Miguel A. Villalona-Calero
,
S. D. Baker
,
+11 authors
Eric K. Rowinsky
Journal of clinical oncology : official journal…
1998
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic profile of the…Â
(More)
Is this relevant?
1998
1998
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft…
K. Mross
,
W. E. Berdel
,
Helmut Fiebig
,
Rajesh Velagapudi
,
Ingo von Broen
,
Clemens Unger
Annals of oncology : official journal of the…
1998
PURPOSE To determine the maximum tolerable dose (MTD), principal toxicity, and pharmacologic behaviour of Cemadotin-HCl, a novel…Â
(More)
Is this relevant?
1995
1995
LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
Monika de Arruda
,
Carmel Cocchiaro
,
+4 authors
Teresa Barlozzari
Cancer research
1995
LU103793 (NSC D-669356) is a new synthetic derivative of Dolastatin 15, an antiproliferative compound which was isolated from the…Â
(More)
Is this relevant?